Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome

Background: Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is associated with potentially life-threatening toxicities, most commonly cytokine release syndrome (CRS) and immune-effector-cell-associated neurotoxicity syndrome (ICANS). These frequent adverse events are managed with the I...

Полное описание

Библиографические подробности

Главные авторы:	Tim Lakomy, Dilara Akhoundova, Henning Nilius, Marie-Noëlle Kronig, Urban Novak, Michael Daskalakis, Ulrike Bacher, Thomas Pabst
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2023-02-01
Серии:	Biomolecules
Предметы:	CAR T-cell therapy adverse events CRS neurotoxicity ICANS tocilizumab
Online-ссылка:	https://www.mdpi.com/2218-273X/13/2/382
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!